drugset / Trial / NCT00384553

Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma

NCT00384553

Phase 1/2 Unknown 30 enrolled University of Magdeburg
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study investigates toxicity and efficacy of 2 x R-DHAP followed by High dose chemotherapy R-TEC and autologous stem cell transplantation in patients with relapsed or refractory aggressive Non- Hodgkins's Lymphoma.

Timeline

Start
2004-06
Primary completion
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified
Subject Cytarabine Small molecule
Subject Dexamethasone Small molecule
Subject Etoposide Small molecule
Subject Rituximab Monoclonal antibody
Subject Treosulfan Small molecule

Indications